Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;21(12):1303-1311.
doi: 10.1080/14737140.2021.1993065. Epub 2021 Oct 22.

Tackling metastatic triple-negative breast cancer with sacituzumab govitecan

Anna R Schreiber  1 , Michelle Andress  2 , Jennifer R Diamond  1
Affiliations
Free article

Tackling metastatic triple-negative breast cancer with sacituzumab govitecan

Anna R Schreiber et al. Expert Rev Anticancer Ther. 2021 Dec.
Free article

Abstract

Introduction Metastatic triple-negative breast cancer (TNBC) is an aggressive cancer with poor survival that is difficult to treat due to a lack of targeted options. Conventional therapies targeting hormone receptors (HR) and human epidermal growth factor 2 (HER2) are ineffective and often chemotherapy is standard-of-care. Sacituzumab govitecan is an antibody drug conjugate (ADC) comprised of an active metabolite of irinotecan, SN-38, bound to a humanized monoclonal antibody targeting trophoblastic cell-surface antigen 2 (Trop-2). Trop-2 is highly expressed on the surface of TNBC cells, making it an attractive target. Areas covered We explore the mechanism, pharmacology, efficacy, safety, and tolerability of sacituzumab govitecan. A literature search was conducted via PubMed using keywords such as 'sacituzumab govitecan,' and 'metastatic TNBC.' Expert opinion Sacituzumab govitecan has promising survival benefits in patients with previously treated mTNBC based on data from the ASCENT trial. Common adverse effects were neutropenia, diarrhea, and nausea, however these effects were manageable with supportive care. Sacituzumab govitecan has shown promise in cancers outside of TNBC, such as urothelial and lung and is being evaluated in HR-positive breast cancers. It is likely we will see this therapy used in combination with other novel targeted agents as current clinical trials mature.

Keywords: IMMU-132; SN-38; Sacituzumab govitecan; antibody drug conjugate (ADC); triple-negative breast cancer (TNBC); trophoblastic cell surface antigen 2 (Trop-2).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources